11 results about "Cholinergic system" patented technology

The application provides a single-chain super-small fluorescent polymer nanodot modified Bacillus subtilis derived nanometer calcium carbonate composite material (SC-PNPs@CaCO3) as a high-sensitivity fluorescent sensing platform for choline acetyltransferase (ChAT) activity detection. The composite material is synthesized through biological mineralization of Bacillus subtilis, the free radical polymerization method is used to prepare the SC-PNPs with positive charges on the surface, and a stable fluorescent sensing system is constructed through self-assembly. Coenzyme A (CoA) is generated in the ChAT catalytic reaction, which can significantly quench the fluorescent signal of the material, realize high-sensitivity detection of the ChAT activity change, and the detection limit reaches 0.00074 mU / mL. The fluorescent sensing platform can realize real-time monitoring of the ChAT activity change, and reveal the regulation effect of the cholinergic signal pathway in the repair process in a skin repair model. The application provides an innovative technical means for choline acetyltransferase activity analysis, and provides a new research direction for exploring the function of the cholinergic system in skin repair and other physiological and pathological processes.

The invention discloses application of an amide compound in preparation of a medicine for treating Alzheimer's disease, and belongs to the technical field of medicines, and the amide compound is N-[(1S)-1-(furan-2-yl) ethyl]-6-nitro-2, 3-dihydro-1, 4-benzodioxin-7-formamide. According to the application of the amide compound in preparation of the medicine for treating the Alzheimer's disease, N-[(1S)-1-(furan-2-yl) ethyl]-6-nitro-2, 3-dihydro-1, 4-benzodioxin-7-formamide can be used for preparing the medicine for treating the Alzheimer's disease by regulating cholinergic system functional defects and inhibiting oxidative stress neuron damage, so that the Alzheimer's disease can be effectively treated. Multi-target accurate intervention on diseases is achieved, the treatment effect is improved through the synergistic effect, and a new thought is provided for treatment of the Alzheimer's disease.

The invention discloses a mussel adhesion spot matrix protein peptide as well as a screening method and application thereof, and belongs to the technical field of bioactive peptides. The peptide sequences of the mussel adhesion spot matrix protein peptide are KPSYTP, MEGIK and SYPQA; the screening method specifically comprises the following steps: (1) virtual enzymolysis of mussel adhesion spot matrix protein; (2) screening the bioactive peptide; and (3) molecular docking. Three bifunctional peptides KPSYTP, MEGIK and SYPQA which are high in activity, high in safety, easy to absorb and brand-new in structure are excavated from mussel adhesion spot matrix protein, can cope with two major pathological links of oxidative stress and cholinergic system dysfunction at the same time, and have unique advantages in the aspect of prevention or auxiliary intervention of neurodegenerative diseases such as Alzheimer's disease and the like; not only can a marine active peptide library be enriched, but also a new solution is provided for developing functional foods, special medical foods or natural raw materials for assisting in intervening neurodegenerative diseases.

The application belongs to the technical field of biological medicine, and particularly relates to a biomarker and application thereof. The application finds that the expression level of a specific subtype of a nicotine acetylcholine receptor of an arrhythmia patient is significantly lower than that of a sinus rhythm population, and the expression of the nicotine acetylcholine receptor in ischemia / reperfusion injury myocardium of a rat and myocardium of a heart failure patient also shows a significant downward trend. Further research finds that the expression loss of the specific subtype of the nAChR significantly increases the risk of arrhythmia. In combination with animal experiment results and human clinical data, it can be seen that the expression defect of the endogenous cholinergic system is closely related to fatal arrhythmia.

The application discloses application of an amide compound in preparation of a drug for treating Alzheimer's disease, belongs to the technical field of medicines, and the amide compound is N-[(1S)-1-(furan-2-yl)ethyl]-6-nitro-2,3-dihydro-1,4-benzodioxin-7-formamide. The application adopts the application of the amide compound in preparation of the drug for treating Alzheimer's disease, and N-[(1S)-1-(furan-2-yl)ethyl]-6-nitro-2,3-dihydro-1,4-benzodioxin-7-formamide realizes precise intervention on diseases through regulation of cholinergic system functional defects and inhibition of oxidative stress neuron damage, improves the treatment effect through a synergistic effect, and provides a new idea for treatment of Alzheimer's disease.

The invention relates to the field of medicinal chemistry, and particularly discloses a piperidine derivative for neurodegenerative diseases, a pharmaceutical composition and application of the piperidine derivative. The piperidine derivative has a structure shown in a general formula (I). In-vivo experiments prove that the compound can effectively improve learning and memory impairment of beta-amyloid protein induced Alzheimer disease model rats, the escape latency is remarkably shortened and the ring penetration frequency is increased in a Morris water maze test, and the behavioral improvement effect of the compound is remarkably superior to that of carristine and can be compared favorably with that of a positive control drug. Meanwhile, the series of compounds can significantly inhibit abnormally increased acetylcholin esterase activity in hippocampal tissues of model rats, have an excellent regulation effect on cholinergic system functions, and show a synergistic effect of cognitive improvement and key pathological link regulation. The compound provided by the invention provides a new and potential candidate drug for treatment of Alzheimer's disease.

The invention belongs to the technical field of biological medicines, and particularly relates to a medicine for treating cardiac dysfunction. The invention finds that the compounds targeting the endogenous cholinergic system can be used for treating cardiac dysfunction; after intervention of the compound, myocardial conduction inhibition caused by ischemia reperfusion (I / R) injury can be effectively reversed, and endogenous cholinergic system function down-regulation caused by I / R injury can be repaired.

The invention discloses a ginkgo biloba extract dropping pill for synergistically improving vascular cognitive impairment through multiple ways and application of the ginkgo biloba extract dropping pill, and belongs to the technical field of new application of medicines. The ginkgo biloba extract dropping pill has a synergistic effect through five ways of oxidative stress regulation, neuroinflammation inhibition, cholinergic system regulation and control, neuronal apoptosis inhibition and intestinal-brain axis regulation, and can up-regulate the activity of antioxidant enzymes, reduce the expression of proinflammatory factors, improve the content of acetylcholine, regulate and control apoptosis-related proteins and repair intestinal flora balance. After intragastric administration, learning memory and social functions can be improved, the content of neurotransmitters in cerebrospinal fluid and brain homogenate can be adjusted, and pathological injuries of hippocampus tissues can be relieved. The mechanism is accurate, the effect is remarkable, a new choice is provided for clinical treatment of the vascular cognitive impairment, and the application prospect is wide.

This invention belongs to the field of functional substance research, specifically relating to a nutritional composition and its use in assisting memory improvement. The nutritional composition provided by this invention comprises the essential active ingredients shown in (I) and (II) below: (I) lysophosphatidylethanolamine; (II) L-α-GPC; wherein the essential active ingredient shown in (I) comprises at least lysophosphatidylethanolamine with a fatty acid chain length of 12-22 carbon atoms, and in the nutritional composition, the mass ratio of the essential active ingredient shown in (I) to the essential active ingredient shown in (II) is 1:(1-1000). The combination of lysophosphatidylethanolamine and L-α-GPC can synergistically assist in improving memory, repairing the cholinergic system in the body, and thereby improving cognitive and behavioral abilities.

The invention discloses an application of a scopolamine model in an acetylcholin esterase inhibitor, and relates to the technical field of medicines.The application comprises the steps that S1, the learning memory of the scopolamine model is improved through a compound; s2, the inhibition effect of the compound on acetylcholin esterase is verified, and the compound is specifically (5S)-1-(3, 4-dihydroxyphenyl)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl) heptyl-3-ketone. A plurality of groups of experiments are designed to prove that the compound can remarkably improve the learning and memory dysfunction of AD model mice induced by scopolamine and has dose dependence, an enzyme activity inhibition experiment shows that the compound has strong inhibitory activity on AChE, the half inhibitory concentration (IC50) of the compound reaches 5.5 nM and is more remarkable than that of a clinical first-line anti-AD drug donepezil (IC50 = 12.2 nM), and the compound can be applied to preparation of anti-AD drugs. As the AChE activity increase is a key factor of cholinergic system injury in the AD pathological process, the compound is speculated to reduce hydrolysis of acetylcholine by inhibiting the AChE activity, and further improve the learning and memory ability of model animals.